237 related articles for article (PubMed ID: 32047993)
21. PSMA-targeted Radiotracers versus
Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
[TBL] [Abstract][Full Text] [Related]
22. Performance of
Bailey J; Piert M
Curr Urol Rep; 2017 Sep; 18(11):84. PubMed ID: 28889366
[TBL] [Abstract][Full Text] [Related]
23. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: Comparative study of multiparametric MRI and PET/CT.
Lee MS; Cho JY; Kim SY; Cheon GJ; Moon MH; Oh S; Lee J; Lee S; Woo S; Kim SH
J Magn Reson Imaging; 2017 Feb; 45(2):597-609. PubMed ID: 27586519
[TBL] [Abstract][Full Text] [Related]
25. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of
López Rodríguez E; Tirado Hospital JL; Álvarez Pérez RM; Gómez Izquierdo L; Jiménez-Hoyuela JM
Actas Urol Esp (Engl Ed); 2020; 44(6):437-443. PubMed ID: 32576406
[TBL] [Abstract][Full Text] [Related]
28. Imaging of prostate cancer with positron emission tomography.
Zimmerman ME; Meyer AR; Rowe SP; Gorin MA
Clin Adv Hematol Oncol; 2019 Aug; 17(8):455-463. PubMed ID: 31449514
[TBL] [Abstract][Full Text] [Related]
29. Prospective Evaluation of
Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
[No Abstract] [Full Text] [Related]
30. Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.
Cuccurullo V; Di Stasio GD; Mansi L
World J Nucl Med; 2018; 17(2):70-78. PubMed ID: 29719480
[TBL] [Abstract][Full Text] [Related]
31. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
32. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
33. PET/MRI in prostate cancer: a systematic review and meta-analysis.
Evangelista L; Zattoni F; Cassarino G; Artioli P; Cecchin D; Dal Moro F; Zucchetta P
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):859-873. PubMed ID: 32901351
[TBL] [Abstract][Full Text] [Related]
34. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
McEwan L; McBean R; Yaxley J; Wong D
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):318-323. PubMed ID: 30840361
[TBL] [Abstract][Full Text] [Related]
35. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
36. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
Crocerossa F; Marchioni M; Novara G; Carbonara U; Ferro M; Russo GI; Porpiglia F; Di Nicola M; Damiano R; Autorino R; Cantiello F
J Urol; 2021 Feb; 205(2):356-369. PubMed ID: 32935652
[TBL] [Abstract][Full Text] [Related]
37. The role of positron emission tomography/computed tomography imaging with radiolabeled choline analogues in prostate cancer.
Navarro-Pelayo Láinez MM; Rodríguez-Fernández A; Gómez-Río M; Vázquez-Alonso F; Cózar-Olmo JM; Llamas-Elvira JM
Actas Urol Esp; 2014 Nov; 38(9):613-21. PubMed ID: 24548475
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
39. [
Hirmas N; Al-Ibraheem A; Herrmann K; Alsharif A; Muhsin H; Khader J; Al-Daghmin A; Salah S
Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
[TBL] [Abstract][Full Text] [Related]
40. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]